Drug Discovery World

APRIL 16, 2023

Vaccine strategies over the last 25 years attempted to induce immune responses against tumour-associated antigens that are not absolutely specific to the tumour,” said presenting author Jeffrey Weber, Deputy Director of the NYU Langone Perlmutter Cancer Center and Laura and Isaac Perlmutter Professor of Oncology at NYU Grossman School of Medicine.

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Discovery World

JULY 26, 2022

Pharmaceutical company BioNTech will deliver the 2022 César Milstein Lecture on 26 July with a focus on how messenger RNA (mRNA) technology can be used within vaccines for cancer and Covid-19. . The lecture will be delivered in two halves by U?ur ahin and Özlem Türeci, co-founders of BioNtech. .

Vaccine 130

Vaccine Immune Response Molecular Biology RNA 130

Drug Target Review

APRIL 26, 2023

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs.

RNA 98

RNA Medical Schools Engineering DNA 98

Drug Discovery World

JULY 8, 2024

Beard Distinguished Professor of Experimental Surgery and the Founding Director of the Translational Research Institute at Duke University, explores the rise of RNA therapeutics. However, the RNA landscape has drastically changed in recent years and we now know that the molecule is more than just a transient, linear carrier of information.

RNA 147

RNA Small Molecule Vaccine FDA Approval 147

The Pharma Data

MARCH 8, 2022

While the development of vaccines was accomplished in a remarkably short timeframe, the identification of direct antiviral treatments has progressed comparatively slowly. In the light of the further risk of pandemics in the future, however, there remains need for direct antiviral drugs and treatments.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

Drug Target Review

FEBRUARY 7, 2024

We had built a machine learning classifier that has been trained to identify amino acid sequences that have the potential to mimic ‘host defense peptides’ from the human innate immune system. Such peptides play a critical role in the machinery for amplifying innate immune responses.

RNA 69

RNA Virus Immune Response Engineering 69

Drug Target Review

JUNE 6, 2023

In this IO arena, we continue to search for additional treatments that can further benefit patients. Generally, IO has been focused on harnessing the anti-tumour activity of certain cancer-fighting T-cells , a key cell type involved in the adaptive immune defense system.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. The company said: “Our preclinical research shows promising results that ASO treatment targeted to PNPLA3 reduces fat accumulation in liver cells.

RNA 130

RNA Vaccine Drugs Disease 130

Drug Target Review

APRIL 3, 2024

Our research demonstrated that GDF-15 acts as a versatile tool for tumours to inhibit the mounting of an effective antitumoral immune response at various steps of its process, including antigen presentation, immune cell activation, and their migration and infiltration into the tumour. in North America) in late 2017.

Science 105

Science Clinical Development DNA Treatment 105

Broad Institute

DECEMBER 6, 2023

The reference, called the Immune Dictionary , appears today in Nature. Using single-cell RNA sequencing to analyze gene expression in individual cells, the researchers have found how 86 major cytokines affect 17 immune cell types in mice. For many immune-mediated diseases, there's no cure or treatment.

Immune Response 138

Immune Response RNA Medical Schools Disease 138

Drug Discovery World

SEPTEMBER 6, 2022

Since 2017, a range of approvals by the FDA has resulted in cell therapies – in particular CAR-T-cell therapies – being used in the treatment of blood cancers. I would expect to see more data coming from the use of cell-based treatments for solid tumours such as breast, ovarian, pancreatic or colorectal cancer.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or protein degradation.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JULY 6, 2021

At ISTH, we are sharing data across all our innovative approaches and collectively, the data reinforce how our pipeline and portfolio may unlock new possibilities in the treatment of rare blood disorders.”. Breaking barriers in hemophilia: helping to evolv e the treatment paradigm. ePoster Abstract # OC48.2 ePoster Abstract # OC48.2

Pharmacokinetics 52

Pharmacokinetics Therapies RNA Treatment 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates. Forward-Looking Statements.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

SugarCone Biotech

MAY 28, 2019

is focused on the response of sarcomas to immunotherapy ( [link] ). The soft tissue sarcomas (STS) have mixed clinical responses to immune checkpoint blockade (ICB) treatment, and it is not clear what drives the variable response. focused on ICB response in melanoma ( [link] ). The paper by Cabrita et al.

Immune Response 52

Immune Response Therapies Production Vaccine 52

Drug Discovery World

FEBRUARY 6, 2023

For example, we noticed in a report that signal of the treatment effect in the data was not aligned with what would be expected. This approach has led to the development of two software packages for RNA sequencing analysis and reproducible ribosomal profiling 1,2. It also helps to quickly address unplanned changes.

Bioinformatics 130

Bioinformatics RNA Vaccine Clinical Trials 130

Drug Discovery World

JUNE 27, 2023

Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity. Future cancer treatment based on antibodies against CD69 could enhance anti-tumour immune responses of CD8+ T cells and lead to more efficient cancer therapies.

Therapies 130

Therapies Immune Response Regulations RNA 130

Drug Target Review

JANUARY 2, 2024

In research published in Scientific Reports , 1 investigators focused on mesenchymal stem cells (MSCs), known for their potential in treating cell defects and regulating immune responses. In the lab, they labelled RNA molecules with fluorescent markers, enabling them to easily locate them within individual cells.

RNA 128

RNA Immune Response Therapies Disease 128

The Pharma Data

DECEMBER 18, 2020

The Moderna COVID-19 Vaccine contains messenger RNA (mRNA), which is genetic material. After a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2.

Vaccine 52

Vaccine FDA Clinical Trials FDA Approval 52

Drug Discovery World

APRIL 12, 2023

Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity.

Vaccine 130

Vaccine Immune Response RNA DNA 130

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. We are even more excited about what the next five years will bring by way of new treatment options for cancer patients.”

Research 130

Research Targeted Protein Degradation Drugs RNA 130

Drug Target Review

MARCH 21, 2024

Could you elaborate on the safety profile observed in the study regarding the administration and treatment with Bobcat mRNA-DMD and how it compares to current therapeutic approaches for Duchenne muscular dystrophy? AAV-based therapies often can’t be dosed more than once due to concerns about an immune response. 2014 Jan 1;3.

Therapies 64

Therapies RNA Immune Response Production 64

Broad Institute

OCTOBER 11, 2023

Manguso, who’d recently graduated from college and was conducting research at the University of Copenhagen as a Fulbright scholar, moved back to the Boston area to be with his mother as she underwent treatment. His mother had a presentation of the disease that suggested her immune system was already on the job.

Research 137

Research Immune Response Clinical Trials Cell Biology 137

Drug Discovery World

JANUARY 4, 2023

They found that neutralising several distinct immunosuppressive mechanisms of the tumour immune microenvironment (TIME) dramatically improved survival rates in laboratory models, pointing to a potential treatment option for this notoriously lethal and unresponsive cancer. . Details of the study .

Immune Response 130

Immune Response Therapies RNA Clinical Trials 130

Broad Institute

JUNE 27, 2024

Neurons were classified by software as either positive for prion protein expression (yellow) before treatment with CHARM (left panel), or negative (purple) after treatment (right panel). ZFPs are also common in human cells, meaning they are less likely to trigger an immune response against themselves than the bacterial Cas9.

Disease 142

Disease Therapies Engineering Clinical Trials 142

Drug Discovery World

OCTOBER 6, 2022

Precision medicine promises a paradigm shift to confidently match the right patients to the right treatment at the right time. Where do we fulfill this need in matching patients to trials, and ultimately to treatments? Both the binary and quantitative have relied on measurement of protein, DNA, and more recently, RNA.

Clinical Trials 130

Clinical Trials Immune Response Therapies Trials 130

Drug Discovery World

OCTOBER 17, 2023

Analysing spatial changes during disease progression or treatment response is key to fully understand pathologies. BN : Yes, spatial analysis will help develop precision medicine, initially through advancing the speed of research and progression of therapeutic approaches and later as part of the treatment regime.

Disease 130

Disease Small Molecule Drugs RNA 130

PLOS: DNA Science

MAY 16, 2024

As soon as the initial RNA genome sequence of the pathogen that would be named SARS-CoV-2 was published, CDC and other organizations began developing diagnostic tests. • identifies parts of the virus to target to provoke an immune response from a vaccine. • reveals viral vulnerability to inspire novel treatments.

Virus 82

Virus DNA RNA Vaccine 82

Codon

AUGUST 27, 2024

When doctors sequenced the DNA and RNA found in Alice’s blood and synovial fluid—the liquid that surrounds and lubricates joints—they found abnormally low levels of genes encoding iron-storing proteins and high levels of epidermal growth factor receptor RNA.

DNA 90

DNA Hospitals Laboratories Virus 90

The Pharma Data

SEPTEMBER 8, 2020

About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Drug Discovery World

APRIL 12, 2023

According to a McKinsey & Company article 2 , new drug modalities (such as RNA therapeutics, protein degraders, cyclopeptides, ADCs, cell and gene therapies) have almost doubled from 11% to 21% of the drug pipeline. For some pharmaceutical companies, like AstraZeneca 3 , 30% of their early pipeline consists of new drug modalities.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130

Codon

APRIL 30, 2023

In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Printed vaccines caused mice to have a faster immune response. Read An easier (and cheaper) way to do single-cell RNA sequencing? Synthetic Biology.

Vaccine 52

Vaccine Engineering DNA RNA 52

Codon

APRIL 30, 2023

In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Printed vaccines caused mice to have a faster immune response. Read An easier (and cheaper) way to do single-cell RNA sequencing? Synthetic Biology.

Vaccine 52

Vaccine Engineering DNA RNA 52

Drug Discovery World

JANUARY 20, 2023

According to a McKinsey & Company article 2 , new drug modalities (such as RNA therapeutics, protein degraders, cyclopeptides, ADCs, cell and gene therapies) have almost doubled from 11% to 21% of the drug pipeline. For some pharmaceutical companies, like AstraZeneca 3 , 30% of their early pipeline consists of new drug modalities.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130

The Pharma Data

SEPTEMBER 9, 2020

Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. producing CD8+ T cell responses, which is thought to promote an anti-viral effect.

Vaccine 52

Vaccine RNA Clinical Trials Immune Response 52

The Pharma Data

JUNE 26, 2021

Sanofi Pasteur, the vaccines global business unit of Sanofi and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

SEPTEMBER 8, 2020

(LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Cambridge, UK.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52